+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

India Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test Location, By Technology (PCR, Sequencing), By Application (Oncology, Infectious Disease, Genetic Testing), And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 160 Pages
  • December 2022
  • Region: India
  • Grand View Research
  • ID: 5712462
The India molecular diagnostics market size is expected to reach USD 1.36 billion by 2030., expanding at a CAGR of 7.49% from 2023 to 2030. The growth is attributed to the rising aging population, growing prevalence of target disease, increase in demand for point-of-care facilities, and technological advancement in diagnostic products.

In India, the prevalence of infectious and vector-borne diseases is high. This includes diseases such as Tuberculosis (TB), H1N1 flu, and vector-borne diseases like malaria and dengue. In addition, CVDs, respiratory infections, diarrhea, and chronic renal diseases further drive the disease burden in the country. According to the NTP report, in 2021, around 4.4 lakh individuals died of TB, which is about 29% of the world's total 1.5 million deaths.

Moreover, the WHO estimated 3 to 5 million cases of severe influenza annually in the country. India also accounts for approximately 4% of the worldwide malaria burden. CVD is another high-prevalence condition in the country, with 54.5 million estimated annual cases, and leads to 4,000 deaths daily. Therefore, the rising burden of such diseases is increasing the demand for diagnostics and fueling the India molecular diagnostics industry.

The market is witnessing rapid technological advancements to obtain low-cost, and highly portable & accurate products. Innovative product launches are also a result of the rising number of R&D and partnership programs. For instance, in August 2022, a UK-based company, Congenica Ltd., partnered with an Indian diagnostic company, Avesthagen Limited, to offer genomic diagnostic services for Avigna Diagnostics business unit, an Indian biotechnology company. This tie-up would reduce diagnostic time by offering a rapid interpretation of NGS data. Similarly, in January 2022, Avesthagen announced a strategic partnership with Wipro, an Indian IT and consulting firm, for the development and commercialization of NGS panels in India.

Amid the COVID-19 pandemic, companies strategically expanded their presence in India by providing cost-effective COVID-19 diagnostic products. For example, in July 2021, Abbott announced the COVID-19 home test kit at a price of around USD 4.07. This increased the product’s target population in the country.

Furthermore, the demand for PoC healthcare facilities is increasing due to government/political support, economic outcomes, rising patient awareness, and advancement in technology. For instance, to curb the gaps in the test-and-treat loop, the Indian government planned to establish POC technology in more than 150,000 government health & wellness centers across the country under the Swasth Bharat, Samridh Bharat initiative. Therefore, such initiatives are boosting the market growth.

India Molecular Diagnostics Market Report Highlights

  • By product, the reagents segment dominated the market in 2022, with a revenue share of 65.38%. An increase in the use of reagents in molecular diagnostic testing & adoption of these tests in nonmedical facilities, as well as high demand for over-the-counter tests, are some of the key factors driving the segment’s growth
  • Based on test location, the central laboratories segment dominated the market in 2022. The point-of-care segment is estimated to grow at a CAGR of 11.61% during the forecast period, owing to an increase in the demand for bedside testing, the need for accurate results, and a rise in awareness about healthcare
  • In 2022, PCR dominated the market with a 75.4% share in the technology segment. The COVID-19 outbreak in 2020 led to a surge in demand for RT-PCR tests for diagnosis amid the pandemic. However, the demand is expected to decline over the coming years due to a rise in vaccinations and a decrease in the number of COVID-19 cases
  • In 2022, by application, infectious disease held the largest market share of 96.5%. Moreover, the oncology segment was also one of the major market shareholders.
  • Some of the key players include Abbott; BD (Becton, Dickinson and Company); Biomérieux SA; Bio-Rad Laboratories, Inc.; Danaher Corporation; Hologic, Inc.; Mylab Discovery Solutions Private Limited; Biogenix Inc. Pvt. Ltd; Trivitron Healthcare; and POCT Services Private Limited


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Indian Molecular Diagnostics Market

What is the estimated value of the Indian Molecular Diagnostics Market?

The Indian Molecular Diagnostics Market was estimated to be valued at $824.16 Million in 2023.

What is the growth rate of the Indian Molecular Diagnostics Market?

The growth rate of the Indian Molecular Diagnostics Market is 7.4%, with an estimated value of $1360 Million by 2030.

What is the forecasted size of the Indian Molecular Diagnostics Market?

The Indian Molecular Diagnostics Market is estimated to be worth $1360 Million by 2030.

Who are the key companies in the Indian Molecular Diagnostics Market?

Key companies in the Indian Molecular Diagnostics Market include Abbott, BD (Becton, Dickinson and Company), bioMérieux SA, Bio, Rad Laboratories, Inc., Danaher Corporation, Hologic, Inc. (Gen Probe), Qiagen and La Roche Ltd.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country - wise market estimation using the bottom - up approach
1.7 Indian Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 India Molecular Diagnostics Market Variables, Trends, & Scope
3.1 India Molecular Diagnostics Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Increase in geriatric population
3.4.1.2 Introduction of technologically advanced products
3.4.1.3 Increase in demand for POC facilities
3.4.1.4 Growing prevalence of target diseases
3.4.2 Market restraint analysis
3.4.2.1 Poor reimbursement policies
3.4.2.2 High prices of molecular diagnostic tests
3.5 India Molecular Diagnostics Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 PESTLE Analysis
Chapter 4 India Molecular Diagnostics Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
4.1 India Molecular Diagnostics Market: Products Movement Analysis
4.1.1 Instruments
4.1.1.1 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
4.1.2 Reagents
4.1.2.1 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
4.1.3 Others
4.1.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5 India Molecular Diagnostics Market - Segment Analysis, by Test Location, 2018 - 2030 (USD Million)
5.1 India Molecular Diagnostics Market: Test Location Movement Analysis
5.1.1 Point - of - Care (PoC)
5.1.1.1 PoC market estimates and forecast, 2018 - 2030 (USD Million)
5.1.2 Self - testing or OTC
5.1.2.1 Self - testing or OTC market estimates and forecast, 2018 - 2030 (USD Million)
5.1.3 Central Laboratories
5.1.3.1 Central Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6 India Molecular Diagnostics Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)
6.1 India Molecular Diagnostics Market: Technology Movement Analysis
6.1.1 Polymerase Chain Reaction
6.1.1.1 Polymerase chain reaction market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.2 PCR market, by Type
6.1.1.2.1 Multiplex PCR
6.1.1.2.1.1 Multiplex PCR market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.2.2 Other PCR
6.1.1.2.2.1 Other PCR market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.3 PCR market, by Product
6.1.1.3.1 Instruments
6.1.1.3.1.1 Instruments PCR market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.3.2 Reagents
6.1.1.3.2.1 Reagents PCR market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.3.3 Others
6.1.1.3.3.1 Others PCR market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2 In Situ Hybridization (ISH)
6.1.2.1 In Situ Hybridization market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.2 Instruments
6.1.2.2.1 Instruments ISH market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.3 Reagents
6.1.2.3.1 Reagents ISH market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.4 Others
6.1.2.4.1 Others ISH market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.1.3.1 INAAT market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.2 Instruments
6.1.3.2.1 Instruments INAAT market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.3 Reagents
6.1.3.3.1 Reagents INAAT market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.4 Others
6.1.3.4.1 Others INAAT market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4 Chips and Microarrays
6.1.4.1 Chips and Microarrays market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.2 Instruments
6.1.4.2.1 Instruments chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.3 Reagents
6.1.4.3.1 Reagents chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.4 Others
6.1.4.4.1 Others chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5 Mass Spectrometry
6.1.5.1 Mass Spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.2 Instruments
6.1.5.2.1 Instruments mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.3 Reagents
6.1.5.3.1 Reagents mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.4 Others
6.1.5.4.1 Others mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
6.1.6 Sequencing
6.1.6.1 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.6.2 Instruments
6.1.6.2.1 Instruments sequencing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.6.3 Reagents
6.1.6.3.1 Reagents sequencing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.6.4 Others
6.1.6.4.1 Others sequencing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.7 Transcription Mediated Amplification (TMA)
6.1.7.1 TMA market estimates and forecast, 2018 - 2030 (USD Million)
6.1.7.2 Instruments
6.1.7.2.1 Instruments TMA market estimates and forecast, 2018 - 2030 (USD Million)
6.1.7.3 Reagents
6.1.7.3.1 Reagents TMA market estimates and forecast, 2018 - 2030 (USD Million)
6.1.7.4 Others
6.1.7.4.1 Others TMA market estimates and forecast, 2018 - 2030 (USD Million)
6.1.8 Others
6.1.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
6.1.8.2 Instruments
6.1.8.2.1 Instruments others market estimates and forecast, 2018 - 2030 (USD Million)
6.1.8.3 Reagents
6.1.8.3.1 Reagents others market estimates and forecast, 2018 - 2030 (USD Million)
6.1.8.4 Others
6.1.8.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 India Molecular Diagnostics Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
7.1 India Molecular Diagnostics Market: Application Movement Analysis
7.1.1 Oncology
7.1.1.1 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.2 Breast cancer
7.1.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.3 Prostate cancer
7.1.1.3.1 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.4 Colorectal cancer
7.1.1.4.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.5 Cervical cancer
7.1.1.5.1 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.6 Kidney cancer
7.1.1.6.1 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.7 Liver cancer
7.1.1.7.1 Liver cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.8 Blood cancer
7.1.1.8.1 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.9 Lung cancer
7.1.1.9.1 Lung cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.10 Other cancers
7.1.1.10.1 Other cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2 Pharmacogenomics
7.1.2.1 Pharmacogenomics market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3 Infectious Diseases
7.1.3.1 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.2 Methicillin - resistant Staphylococcus Aureus (MRSA)
7.1.3.2.1 MRSA market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 Clostridium difficile
7.1.3.3.1 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 Vancomycin - Resistant Enterococci (VRE)
7.1.3.4.1 VRE market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.5 Carbapenem - resistant bacteria
7.1.3.5.1 Carbapenem - resistant bacteria market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.6 Flu
7.1.3.6.1 Flu market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.7 Respiratory Syncytial Virus (RSV)
7.1.3.7.1 RSV market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.8 Candida
7.1.3.8.1 Candida market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.9 Tuberculosis (TB) and drug - resistant TBA
7.1.3.9.1 TB and drug - resistant TB market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.10 Meningitis
7.1.3.10.1 Meningitis market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.11 Gastrointestinal panel testing
7.1.3.11.1 Gastrointestinal panel testing market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.12 Chlamydia
7.1.3.12.1 Chlamydia market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.13 Gonorrhoea
7.1.3.13.1 Gonorrhoea market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.14 HIV
7.1.3.14.1 HIV market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.15 Hepatitis C
7.1.3.15.1 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.16 Hepatitis B
7.1.3.16.1 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.17 Other infectious disease market
7.1.3.17.1 Other infectious disease market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4 Genetic Testing
7.1.4.1 Genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4.2 Newborn screening
7.1.4.2.1 Newborn screening market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4.3 Predictive and presymptomatic testing
7.1.4.3.1 Predictive and presymptomatic testing market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4.4 Other genetic testing
7.1.4.4.1 Other genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
7.1.5 Neurological Diseases
7.1.5.1 Neurological diseases market estimates and forecast, 2018 - 2030 (USD Million)
7.1.6 Cardiovascular Diseases
7.1.6.1 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
7.1.7 Others
7.1.7.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 India Molecular Diagnostics Market - Competitive Analysis
8.1 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
8.2 Major Deals & Strategic Alliances Analysis
8.3 Recent Developments and Impact Analysis, by Key Market Participants
8.3.1 New Product Launches
8.3.2 Mergers and Acquisitions
8.3.3 Partnerships and Strategic Collaborations
8.3.4 Conferences, Marketing, & promotions
8.4 Vendor Landscape
8.4.1 List of key distributors
8.4.2 Key company market share analysis, 2022
8.4.3 Key company market share analysis, PCR Kits, by Value, 2022
8.4.4 Key company market share analysis, PCR Kits, by Volume, 2022
8.5 Public Companies
8.5.1 Company market position analysis (2022)
8.5.2 Competitive Dashboard Analysis
8.6 Indian MDx companies (domestic and international product portfolio)
8.6.1 Meril Life Sciences Pvt. Ltd.
8.6.1.1 Product benchmarking
8.6.2 Mylab Discovery Solutions Pvt. Ltd.
8.6.2.1 Product benchmarking
8.6.3 Molbio Diagnostics Pvt. Ltd.
8.6.3.1 Product benchmarking
8.6.4 Bio - Techne
8.6.4.1 Product benchmarking
8.6.5 3B BlackBio Biotech India Ltd.
8.6.5.1 Product benchmarking
8.6.6 HUWEL Lifesciences Pvt. Ltd
8.6.6.1 Product benchmarking
8.6.7 GCC Biotech India Pvt Ltd
8.6.7.1 Product benchmarking
8.6.8 Bhat Bio - Tech India (P) Limited
8.6.8.1 Product benchmarking
8.6.9 Trivitron Healthcare Pvt. Ltd.
8.6.9.1 Product benchmarking
8.6.10 Medsource Ozone Biomedicals Pvt. Ltd.
8.6.10.1 Product benchmarking
8.7 Private Companies
8.7.1 List of key emerging companies /technology disruptors/innovators
8.7.2 Regional network map
8.8 Company Profiles
8.8.1 Abbott
8.8.1.1 Company overview
8.8.1.2 Alere, Inc.
8.8.1.3 Financial performance
8.8.1.4 Product benchmarking
8.8.1.5 Strategic initiatives
8.8.2 BD (Becton, Dickinson and Company)
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 bioMérieux SA
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 Bio - Rad Laboratories, Inc.
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 Danaher Corporation
8.8.5.1 Company overview
8.8.5.2 Cepheid
8.8.5.3 Beckman Coulter
8.8.5.4 Leica Biosystems
8.8.5.5 Financial performance
8.8.5.6 Product benchmarking
8.8.5.7 Strategic initiatives
8.8.6 Hologic, Inc. (Gen Probe)
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 Qiagen
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 F. Hoffmann - La Roche Ltd
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives
8.8.9 Siemens Healthineers
8.8.9.1 Company overview
8.8.9.2 Financial performance
8.8.9.3 Product benchmarking
8.8.9.4 Strategic initiatives
8.8.10 Sysmex Corporation
8.8.10.1 Company overview
8.8.10.2 Financial performance
8.8.10.3 Product benchmarking
8.8.10.4 Strategic initiatives
8.8.11 DiaSorin S.p.A.
8.8.11.1 Company overview
8.8.11.2 Financial performance
8.8.11.3 Product benchmarking
8.8.11.4 Strategic initiatives
8.8.12 Mylab Discovery Solutions Private Limited.
8.8.12.1 Company overview
8.8.12.2 Financial performance
8.8.12.3 Product benchmarking
8.8.12.4 Strategic initiatives
8.8.13 Biogenix Inc. Pvt. Ltd.
8.8.13.1 Company overview
8.8.13.2 Financial performance
8.8.13.3 Product benchmarking
8.8.13.4 Strategic initiatives
8.8.14 Trivitron Healthcare.
8.8.14.1 Company overview
8.8.14.2 Financial performance
8.8.14.3 Product benchmarking
8.8.14.4 Strategic initiatives
8.8.15 POCT Services Private Limited
8.8.15.1 Company overview
8.8.15.2 Financial performance
8.8.15.3 Product benchmarking
8.8.15.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 List of molecular diagnostic multiplex products
Table 4 List of key emerging companies /technology disruptors/innovators
Table 5 India molecular diagnostic market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 6 India molecular diagnostic market estimates and forecasts, by test location, 2018 - 2030 (USD Million)
Table 7 India molecular diagnostic market estimates and forecasts, by technology, 2018 - 2030 (USD Million)
Table 8 India molecular diagnostic market estimates and forecasts, by application, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 India Molecular Diagnostics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 India molecular diagnostics market snapshot, 2022
Fig. 10 Parent market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Sources of healthcare financing according to country income, 2020 (%)
Fig. 15 Porter’s five forces analysis
Fig. 16 India molecular diagnostics market: Products outlook and key takeaways
Fig. 17 India molecular diagnostics market: Products movement analysis
Fig. 18 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 India molecular diagnostics market: Test location outlook and key takeaways
Fig. 22 India molecular diagnostics market: Test location movement analysis
Fig. 23 PoC market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Self - testing or OTC market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Central laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 India molecular diagnostics market: Technology outlook and key takeaways
Fig. 27 India molecular diagnostics market: Technology movement analysis
Fig. 28 Polymerase chain reaction market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Multiplex PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Other PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Instruments PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Reagents PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Others PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 ISH market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Instruments ISH market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Reagents ISH market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Others ISH market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 INAAT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Instruments INAAT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Reagents INAAT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others INAAT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Instruments chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Reagents chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Others chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Instruments mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Reagents mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Others mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Instruments sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Reagents sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Others sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 TMA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Instruments TMA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Reagents TMA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Others TMA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Instruments others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Reagents others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 India Molecular Diagnostics market: Application outlook and key takeaways
Fig. 63 India molecular diagnostics market: Application movement analysis
Fig. 64 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Breast cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Liver cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Lung cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Other cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Pharmacogenomics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 MRSA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 VRE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Carbapenem - resistant bacteria market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Flu market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 RSV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Candida market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 TB and drug - resistant TB market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Meningitis cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Gastrointestinal panel testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Chlamydia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 HIV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Other infectious disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Newborn screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Predictive and presymptomatic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Other genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Neurological diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Competition categorization
Fig. 100 Strategy mapping
Fig. 101 Company market share analysis -India molecular diagnostics market, 2022
Fig. 102 Company market share analysis -India molecular diagnostics market, PCR Kits, by Value, 2022
Fig. 103 Company market position analysis
Fig. 104 Company market position analysis
Fig. 105 Competitive dashboard analysis
Fig. 106 Regional network map

Companies Mentioned

  • Abbott
  • BD (Becton, Dickinson and Company)
  • bioMérieux SA
  • Bio - Rad Laboratories, Inc.
  • Danaher Corporation
  • Hologic, Inc. (Gen Probe)
  • Qiagen
  • F. Hoffmann - La Roche Ltd
  • Siemens Healthineers
  • Sysmex Corporation
  • DiaSorin S.p.A.
  • Mylab Discovery Solutions Private Limited.
  • Biogenix Inc. Pvt. Ltd.
  • Trivitron Healthcare.
  • POCT Services Private Limited

Methodology

Loading
LOADING...